Dayu Lv, PhD

Starting as a mechanical engineer with training in software development, Dr. Dayu Lv was amazed by the beauty and complexity of the human body, and immersed into the field of modeling of metabolic systems, especially in blood glucose and regulatory hormones network.

He has developed pharmacokinetic models of exogenous glucagon and insulin (in various routes). These models have been adopted in the in silico simulation platform, the UVA/Padova type 1 diabetes simulator, which was approved by the FDA as a substitute for preclinical trials of certain insulin treatments.

Based on the T1D simulator, Dr. Dayu Lv has also developed various intervention strategies, algorithms, which led to my interests of further investigation on different impacts on glucose dynamics. The simulation works will provide helpful insights for glycemic management for T1D subjects.

Professional Education

• Bachelor’s in Mechanical Engineering, University of Science and Technology of China, 2001
• Master’s in Machine Software Development, University of Science and Technology of China, 2004
• PhD in Metabolism Modeling and Simulation, University of Notre Dame, 2011
• Postdoctorla Fellow, University of Virginia, Center for Diabetes Technology, Present

Areas of focus: Artificial Pancreas, Closed-Loop, Simulation

1DP3DK106826-01 Breton (PI)                                          08/01/15 – 07/31/19
Models, Signals, and Distributed Bio-Behavioral Control of Exercise in Diabetes
This project proposes to test the safety and efficacy of the exercise-informed Artificial Pancreas system with respect to multiple glucose control modes in three clinical trials.
Role: Research Associate
2-SRA-2016-291-Q-R          Campos-Nanez (PI)                            08/01/16 – 07/31/18
T1D Behavioral Simulator for Decision Support Tool In-Silico Validation
The main goal is to augment the FDA approved UVA/Padova type 1 simulator with a Behavioral Simulator, i.e., a component to mimic every-day behavior around meals, exercise and self-treatment; this component will be critical in the development of new decision support systems.
Role: Research Associate

• Breton, SD. Patek, Lv, D., et al. Continuous glucose monitoring and insulin informed advisory system with automated titration and dosing of insulin reduces glucose variability in type 1 diabetes mellitus, Diabetes Technology & Therapeutics, 20(8):531-540, 2018. PMCID: PMC6080127
• Visentin, E. Campos-Náñez, M Schiavon, D Lv, et al., The UVA/Padova type 1 diabetes simulator goes from single meal to single day, J. Diabetes Sci. Technol. 12(2):273-281, 2018. PMCID: PMC5851236
• Pateck, D. Lv, E Campos-Nanez, M Breton, Retrospective optimization of daily insulin therapy parameters: Control subject to a regenerative disturbance process, IFAC-PapersOnLine 49(7):773-778, 2016
• Pateck, D Lv, EA Ortiz, et al. Empirical representation of blood glucose variability in a compartmental model, Prediction Methods for Blood Glucose Concentration, 133-157, 2016
• Lv, SD. Kulkarni, A. Chan, S. Keith, Pettis R, et al. Pharmacokinetic Model of the Transport of Fast-Acting Insulin From the Subcutaneous and Intradermal Spaces to Blood. J Diabetes Sci Technol. 9(4):831-40, 2015. PMCID: PMC4525663.
• Man, F. Micheletto F, D. Lv, M. Breton, B. Kovatchev, C. Cobelli. The UVA/PADOVA Type 1 Diabetes Simulator: New Features. J Diabetes Sci Technol. 8(1):26-34, 2014. PMCID: PMC4454102.
• Lv, MD. Breton, LS. Farhy. Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients, Diabetes Technol Ther. 15(11):935-41, 2013. PMCID: PMC3818836.

Other publications can be found here.